Skip to main content

Research Repository

Advanced Search

Professor Adrian Brunt's Outputs (59)

When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management (2021)
Journal Article
Obeng-Gyasi, S., Coles, C. E., Jones, J., Sacks, R., Lightowlers, S., Bliss, J. M., …Kalinsky, K. (2021). When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. American Society of Clinical Oncology educational book, 41(41), e79-e89. https://doi.org/10.1200/edbk_320691

In the care of patients with operable breast cancer, there has been a shift toward increasing use of neoadjuvant therapy. There are benefits to neoadjuvant therapy, such as monitoring for response, as well as an increased rate of breast conservation... Read More about When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management.

4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial (2021)
Journal Article
Hoskin, P., Popova, B., Schofield, O., Brammer, C., Robinson, M., Brunt, A. M., …Kirkwood, A. A. (2021). 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology, 22(3), 332-340. https://doi.org/10.1016/S1470-2045%2820%2930686-0

BACKGROUND: The optimal radiotherapy dose for indolent non-Hodgkin lymphoma is uncertain. We aimed to compare 24 Gy in 12 fractions (representing the standard of care) with 4 Gy in two fractions (low-dose radiation). METHODS: FoRT (Follicular Radioth... Read More about 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer (2020)
Report
Brunt, A. M., Haviland, J. S., Sydenham, M., Agrawal, R. K., Algurafi, H., Alhasso, A., …Yarnold, J. R. (2020). Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

PURPOSE: Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcom... Read More about Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.

Breast Cancer Management Guidelines During COVID-19 Pandemic (2020)
Journal Article
Gowda S, M., Katherine Kabeer, K., Jafferbhoy, S., Marla, S., Soumian, S., Misra, V., …Brunt, A. M. (2020). Breast Cancer Management Guidelines During COVID-19 Pandemic. Indian Journal of Surgery, 82, 251-258. https://doi.org/10.1007/s12262-020-02466-7

The coronavirus disease (COVID-19) pandemic in 2020 has brought about complex challenges in healthcare delivery. With the new rules of lockdown and social distancing and with resources diverted to the management of COVID-19, there are difficulties in... Read More about Breast Cancer Management Guidelines During COVID-19 Pandemic.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial (2020)
Journal Article
Brunt, A. M., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., …Management Group, F. T. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395(10237), 1613 - 1626. https://doi.org/10.1016/S0140-6736%2820%2930932-6

BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after pri... Read More about Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial (2020)
Journal Article
King, M. T., Link, E. K., Whelan, T. J., Olivotto, I. A., Kunkler, I., Westenberg, A. H., …Lavery, B. (2020). Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncology, 21(5), 685-698. https://doi.org/10.1016/s1470-2045%2820%2930085-1

Background
BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boost and hypofractionation in patients with non-low-risk ductal carcinoma in situ following breast-conserving surgery and w... Read More about Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial (2019)
Journal Article
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Murray Brunt, A., Nemsadze, G., …C. Turner, N. (2020). Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38(5), 423 - 433. https://doi.org/10.1200/JCO.19.00368

PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been assoc... Read More about Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial (2019)
Journal Article
Fernando, I. N., Bowden, S. J., Herring, K., Brookes, C. L., Ahmed, I., Marshall, A., …Rea, D. W. (2020). Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiotherapy and Oncology, 142, 52-61. https://doi.org/10.1016/j.radonc.2019.10.014

BACKGROUND: The optimal sequence of adjuvant chemotherapy and radiotherapy for breast cancer is unknown. SECRAB assesses whether local control can be improved without increased toxicity. METHODS: SECRAB was a prospective, open-label, multi-centre, ph... Read More about Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer (2019)
Journal Article
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., …Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5(11), 1556 - 1556. https://doi.org/10.1001/jamaoncol.2019.2526

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating... Read More about Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer.

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial (2019)
Journal Article
Mittendorf, E. A., Lu, B., Melisko, M., Price Hiller, J., Bondarenko, I., Brunt, A. M., …Peoples, G. E. (2019). Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clinical Cancer Research, 25(14), 4248-4254. https://doi.org/10.1158/1078-0432.ccr-18-2867

long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma (2019)
Journal Article
Hoskin, P., Kirkwood, A., Popova, B., Schofield, O., Brammer, C., Robinson, M., …Clifton-Hadley, L. (2019). long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma. Hematological Oncology, 37(S2), 219 - 220. https://doi.org/10.1002/hon.34_2630

Supplement article.

16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654) (2019)
Journal Article
Winters, Z., Roberts, N., McCartan, N., Potyka, I., Brunt, M., Maxwell, A., …Williams, N. (2019). 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654). EJSO - European Journal of Surgical Oncology, 45(5), 881. https://doi.org/10.1016/j.ejso.2019.01.202

Background: Oncological safety of treating multiple ipsilateral breast cancers (MIBC) using therapeutic mammoplasty (TM) compared to mastectomy remains uncertain. A National Institute for Health Research (NIHR) - funded MIAMI feasibility phase random... Read More about 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654).

Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK (2019)
Journal Article
Brunt. (2019). Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK. Annals of Surgical Oncology, 58 - 60

Meeting abstract, from the 20th Annual Meeting of the American-Society-of-Breast-Surgeons Conference, Dallas, Texas, 30 Apr - 5 May, 2019.

Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003) (2018)
Presentation / Conference
Coles, C., Griffin, C., Kirby, A., Haviland, J., Titley, J., Benstead, K., …Yarnold, J. (2018, December). Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003). Presented at 2018 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA

Meeting abstract (Abstract GS4-05 from 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas).

FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015) (2018)
Journal Article
Brunt, A., Haviland, J., Sydenham, M., Algurafi, H., Alhasso, A., Bliss, P., …Yarnold, J. (2018). FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology - Biology - Physics, 102(5), 1603 -1604. https://doi.org/10.1016/j.ijrobp.2018.08.049

Conference abstract.

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial (2018)
Journal Article
Velikova, G., Jane Williams, L., Willis, S., Michael Dixon, J., Loncaster, J., Hatton, M., …Yuille, F. (2018). Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology, 19(11), 1516 - 1529. https://doi.org/10.1016/s1470-2045%2818%2930515-1

Background
Postmastectomy radiotherapy in patients with four or more positive axillary nodes reduces breast cancer mortality, but its role in patients with one to three involved nodes is controversial. We assessed the effects of postmastectomy radio... Read More about Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (2018)
Journal Article
Corrie, P., Marshall, A., Nathan, P., Lorigan, P., Gore, M., Tahir, S., …Coltart, R. (2018). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of oncology, 29(8), 1843 -1852. https://doi.org/10.1093/annonc/mdy229

Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recur... Read More about Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.